R
3.42
0.13 (3.95%)
| Penutupan Terdahulu | 3.29 |
| Buka | 3.24 |
| Jumlah Dagangan | 1,104,319 |
| Purata Dagangan (3B) | 2,376,509 |
| Modal Pasaran | 370,120,000 |
| Harga / Buku (P/B) | 1.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -2.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.15% |
| Nisbah Semasa (MRQ) | 9.19 |
| Aliran Tunai Operasi (OCF TTM) | -208.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -109.28 M |
| Pulangan Atas Aset (ROA TTM) | -34.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Rocket Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
-0.8
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.75 |
|
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.73% |
| % Dimiliki oleh Institusi | 93.45% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Monaco Asset Management Sam | 30 Sep 2025 | 2,892,261 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 263.00 (JP Morgan, 7,590.06%) | Jual |
| Median | 9.50 (177.78%) | |
| Rendah | 7.00 (Leerink Partners, 104.68%) | Pegang |
| Purata | 72.25 (2,012.57%) | |
| Jumlah | 2 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 3.33 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 18 Nov 2025 | 8.00 (133.92%) | Beli | 2.94 |
| JP Morgan | 18 Nov 2025 | 263.00 (7,590.06%) | Jual | 2.94 |
| Chardan Capital | 14 Oct 2025 | 11.00 (221.64%) | Beli | 4.27 |
| Leerink Partners | 03 Oct 2025 | 7.00 (104.68%) | Pegang | 3.15 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference |
| 06 Nov 2025 | Pengumuman | Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress |
| 14 Oct 2025 | Pengumuman | Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) |
| 10 Oct 2025 | Pengumuman | Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |